Novel therapeutics show potential to raise platelet counts in patients with immune thrombocytopenia, suggesting a shift from conventional methods.
Introduction Immune thrombocytopenia (ITP) is anautoimmune bleeding disorder; its management is shifting from empiricimmunosuppression and splenectomy to targeted, pathway-specific drugs thatraise platelet counts with fewer long-term toxicities.
No takes yet. Share an insight, caveat, or question.
Kun Huang (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: